Treatment of patients with postoperative recurrent-metastatic gastrointestinal stromal tumor

De-sen WAN

DOI: https://doi.org/10.3760/cma.j.issn.1006-9801.2006.08.006

2006-01-01

Abstract:Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumours in the wall of gastrointestinal tract. Although surgery is still the main treatment for GIST, surgery does not cure recurrent and metastatic GIST. As advocated by the NCCN, for patients with GIST recurs and metastasizes, imatinib should be the fist-line therapy. Patients with advanced and recurrent-metastatic GIST should take imatinib continuously until they had resistance to imatinib and the drug could not control the tumor. Though postoperative recurrent-metastatic GIST recurs and metastasizes in approximately 100 % of them, surgery is indicated if all disease can be removed and is also encouraged if all visible tumor can be removed once the maximum response to imatinib is attained. Imatinib in the neoadjuvant and adjuvant settings are currently conducted by many center. SU11248, a multiple-target tyrosine kinase inhibits with antitumor and antiangiogenic properties, is being evaluated as a treatment option for patients with GIST that is not controlled with imatinib. It is reported that 65 % of patients with resistance to imatinib benefit from SU11248. Ultimately, the selection and timing of therapeutic interventions is crucial and to reduce the incidence of and risks for recurrent disease, optimize disease control, improve patients' quality of life, and prolong their survival.